Dare Bioscience (DARE) Amortization of Deferred Charges (2015 - 2025)
Dare Bioscience's (DARE) quarterly Amortization of Deferred Charges came in at -$53371.0 in Q4 2025, down 187.46% YoY from $61023.0 in Q4 2024, and down 142.95% on a QoQ basis from $124251.0 in Q3 2025.
Dare Bioscience (DARE) Amortization of Deferred Charges (2015 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 5 years of Amortization of Deferred Charges data on file, last reported at -$53371.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges fell 187.46% year-over-year to -$53371.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $82502.0 (down 74.0% YoY) and the FY2025 annual result came in at $82502.0, down 74.0% from the prior year.
- Amortization of Deferred Charges fell to -$53371.0 in Q4 2025, from $124251.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $170205.0 in Q2 2024 to a low of -$53371.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -53,371.00 |
| Dec 31, 2025 | -53,371.00 |
| Sep 30, 2025 | 124,251.00 |
| Sep 30, 2025 | 124,251.00 |
| Jun 30, 2025 | 1,578.00 |
| Jun 30, 2025 | 1,578.00 |
| Mar 31, 2025 | 10,044.00 |
| Mar 31, 2025 | 10,044.00 |
| Dec 31, 2024 | 61,023.00 |
| Dec 31, 2024 | 61,023.00 |
| Sep 30, 2024 | 85,431.00 |
| Sep 30, 2024 | 85,431.00 |
| Jun 30, 2024 | 170,205.00 |
| Jun 30, 2024 | 170,205.00 |
| Mar 31, 2024 | 659.00 |
| Mar 31, 2024 | 659.00 |
| Mar 31, 2017 | 610,000.00 |
| Mar 31, 2017 | 610,000.00 |
| Dec 31, 2016 | 85,000.00 |
| Dec 31, 2016 | 85,000.00 |